Folate-related DNA endpoints

Folate-related DNA endpoints refer to a collective set of molecular and cytogenetic markers used to assess the status of one-carbon metabolism and its effects on genomic integrity and epigenetic stability. Folate is an essential co-factor required for the de novo synthesis of thymidylate (dTMP) and the production of S-adenosylmethionine, the primary methyl donor for DNA methylation [1]. When folate levels are deficient or the pathway is pharmacologically inhibited, deoxyuridine monophosphate (dUMP) accumulates, leading to the massive misincorporation of uracil into DNA, which triggers error-prone repair and double-strand breaks [2]. Furthermore, insufficient folate leads to global DNA hypomethylation, which can destabilize the genome and activate oncogenes [3]. These endpoints are critical in oncology and nutritional research, as they provide a mechanistic link between folate status and the development of diseases such as colorectal cancer and neural tube defects [4]. In drug development, these endpoints serve as vital biomarkers for measuring the efficacy and toxicity of antifolate chemotherapies like methotrexate and 5-fluorouracil, which purposefully disrupt these processes to inhibit tumor cell proliferation [5].

Other names

DNA biomarkers of folate statusFolate-mediated one-carbon metabolism endpointsGenomic stability markersFolate-sensitive DNA markers

Interacting drugs typically inhibit enzymes such as dihydrofolate reductase (DHFR) or thymidylate synthase (TYMS), which disrupts the availability of methyl groups and nucleotides, directly altering DNA endpoints like uracil content and methylation levels.